Form 4: Avanos Medical SVP Kerr Holbrook Reports Share Transactions Following Vesting of Restricted Share Units

A Form 4 filing reveals that Avanos Medical's SVP, Chief Commercial Officer Kerr Holbrook, engaged in transactions involving common stock following the vesting of performance-based and time-based restricted share units.

Summary

• On March 4, 2025, Kerr Holbrook, SVP, Chief Commercial Officer of Avanos Medical, Inc., had performance-based restricted share units (PRSUs) vest, resulting in the acquisition of 5,145 shares.
• Following the vesting, shares were surrendered to the issuer to satisfy tax withholding obligations related to both the vested PRSUs (1,803 shares) and time-based restricted share units (TRSUs) (1,543 shares).
• Holbrook's total beneficially owned shares after these transactions amounted to 89,047.
• The transactions also include the acquisition of 117 shares on December 31, 2024, and 1,000 shares on June 30, 2024, under the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates